Quick Answer
Damora Therapeutics, Inc. reported Stockholders Equity of $240.38 million for the year ending 2025.
- Damora Therapeutics, Inc. showed an increase of +1,418.4% in Stockholders Equity from 2024 to 2025.
- This data is from Damora Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2019: -$41.89 million | Q3 2019: -$48.06 million | Q1 2020: -$77.03 million | Q2 2020: -$82.55 million | Q3 2020: -$91.74 million | Q1 2021: $152.57 million | Q2 2021: $141.43 million | Q3 2021: $129.62 million | Q1 2022: $101.31 million | Q2 2022: $85.07 million | Q3 2022: $72.73 million | Q1 2023: $50.33 million | Q2 2023: $43.70 million | Q3 2023: $37.38 million | Q1 2024: $28.16 million | Q2 2024: $23.59 million | Q3 2024: $20.94 million | Q1 2025: $13.71 million | Q2 2025: $10.95 million | Q3 2025: $8.01 million.
- Over the full 8 years of available data (2018 to 2025), Damora Therapeutics, Inc.'s Stockholders Equity has grown by 810.4%.
- Historical annual values: Fiscal year 2025: $240.38 million | Fiscal year 2024: $15.83 million | Fiscal year 2023: $32.33 million | Fiscal year 2022: $61.75 million | Fiscal year 2021: $117.22 million | Fiscal year 2020: $165.49 million | Fiscal year 2019: -$71.15 million | Fiscal year 2018: -$33.84 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: